{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:27:50Z","timestamp":1786969670004,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Non-Small Cell Lung Carcinoma (NSCLC) is frequently associated with driver mutations in the epidermal growth factor receptor (EGFR) gene. Activating EGFR mutations occur in approximately 14\u201338% of NSCLC cases, with common mutations\u2014exon 19 deletions and exon 21 L858R\u2014accounting for nearly 90%. Uncommon mutations, including G719X, S768I, L861Q, and exon 20 insertions (Ins20), excluding T790M, comprise about 10\u201315% and are increasingly recognized for their therapeutic implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study profiled uncommon EGFR mutations in NSCLC patients at a tertiary cancer care center. EGFR mutation testing was performed on 4463 samples using a commercial detection kit. Statistical analyses were conducted using Python 3, with P &lt; 0.05 considered significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>EGFR mutations were identified in 32.2% (1441\/4463) of cases, of which 85.37% were common and 9.92% were uncommon (excluding T790M). Among uncommon mutations, 77.7% were single and 22.2% were compound. The most frequent single mutation was Ins20 (27%), followed by L861Q (25.7%) and G719X (20.8%). These mutations were most common in patients aged 51\u201370 years, predominantly with adenocarcinoma histology. Nodal staging was available for 118 patients, while both nodal and treatment data were available for 112. No significant association was observed between mutation subtype and nodal staging (P = 0.918). However, a significant correlation was found between mutation subtype, distant metastasis, and treatment modality (P &lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Uncommon EGFR mutations in NSCLC are associated with advanced-stage presentation. While nodal staging is independent of mutation subtype, treatment strategies are strongly genotype-driven, underscoring the importance of precise molecular characterization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1710_25","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T08:00:20Z","timestamp":1786780820000},"page":"525-530","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of uncommon epidermal growth factor receptor (EGFR) Mutations in Non-Small Cell Lung Carcinoma (NSCLC): A tertiary cancer care center experience"],"prefix":"10.4103","volume":"22","author":[{"given":"Chumki","family":"Bhattacharjee","sequence":"first","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sabnam","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saheli","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Vinarkar","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Parihar","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Kumar","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology and Haematology, Tata Medical Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","article-title":"Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology","volume":"23","author":"J\u00e4nne","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR Exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","article-title":"EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples","volume":"66","author":"Ellison","year":"2013","journal-title":"J Clin Pathol"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"102080","DOI":"10.1016\/j.canep.2021.102080","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes","volume":"76","author":"John","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/ijerph20010758","article-title":"Mutational analysis of EGFR mutations in non-small cell lung carcinoma\u2014An Indian perspective of 212 patients","volume":"20","author":"Kaler","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"(Suppl 2)","key":"R10-20260817","doi-asserted-by":"crossref","first-page":"S712","DOI":"10.4103\/jcrt.jcrt_653_22","article-title":"Frequency of EGFR mutations in lung adenocarcinoma patients-A study from tertiary cancer center of South India","volume":"19","author":"Nayanar","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4103\/jcrt.jcrt_1986_21","article-title":"Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India","volume":"19","author":"Thomas","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"e2400353","DOI":"10.1200\/GO-24-00353","article-title":"Prevalence of EGFR mutations in patients with resected stage I to III nonsquamous non-small cell lung cancer: Results of India cohort","volume":"11","author":"Batra","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.3390\/ijms24108878","article-title":"Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): New lights for an unmet medical need","volume":"24","author":"Pretelli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.3892\/ol.2017.5980","article-title":"Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations","volume":"13","author":"Krawczyk","year":"2017","journal-title":"Oncol Lett"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, Non Exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"101064","DOI":"10.1016\/j.currproblcancer.2024.101064","article-title":"Current management of uncommon EGFR mutations in non-small cell lung cancer","volume":"49","author":"Trinh","year":"2024","journal-title":"Curr Prob Cancer"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"10861","DOI":"10.2147\/CMAR.S266069","article-title":"Oncogenic genetic alterations in non-small-cell lung cancer (NSCLC) in Southwestern China","volume":"12","author":"Ma","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"e61561","DOI":"10.1371\/journal.pone.0061561","article-title":"EGFR mutations in Indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy","volume":"8","author":"Noronha","year":"2013","journal-title":"PLoS ONE"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/curroncol29010007","article-title":"Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients","volume":"29","author":"Liu","year":"2021","journal-title":"Curr Oncol"},{"key":"R20-20260817","first-page":"1204635","article-title":"Clinical characteristics and prognosis of patients with uncommon EGFR mutations in non-small cell lung cancer: a large-scale retrospective study","volume":"13","author":"Zheng","year":"2023","journal-title":"Front Oncol"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/pcm-22-14","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer","volume":"5","author":"Russano","year":"2022","journal-title":"Precis Cancer Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1710_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:01:28Z","timestamp":1786968088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1710_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1710_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}